{"id":"W2624305751","doi":"10.1200/jco.2017.35.15_suppl.1089","title":"Overall survival (OS) in patients (Pts) with diagnostic positive (Dx+) breast cancer: Subgroup analysis from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in AR+ triple-negative breast cancer (TNBC) treated with 0-1 prior lines of therapy.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Enzalutamide; Clinical endpoint; Internal medicine; Breast cancer; Prostate cancer; Oncology; Subgroup analysis; Triple-negative breast cancer; Phases of clinical research; Cancer; Androgen receptor; Gastroenterology; Clinical trial; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001378638,0.0006459592,0.001453524,0.0005505366,0.0002184909,0.0005624869,0.0003500349,0.0005801672,0.001753663],"category_scores_gemma":[0.001041643,0.000244278,0.002829669,0.0004730616,0.000261273,0.0003679321,0.0004285143,0.00081006,0.0002442023],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004525379,"about_ca_system_score_gemma":0.0003811947,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000578561,"about_ca_topic_score_gemma":0.001586457,"domain_scores_codex":[0.99955,0.0001606474,0.00005336232,0.0001103636,0.00006162536,0.00006398095],"domain_scores_gemma":[0.9995376,0.0001433099,0.000131907,0.00005377423,0.00002871232,0.0001046816],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5688513,0.002549862,0.3203442,0.001658906,0.01941875,0.0008642975,0.000267569,0.003956952,0.01919771,0.000155629,0.003025367,0.05970943],"study_design_scores_gemma":[0.08173148,0.1027569,0.7749773,0.0001998781,0.02380533,0.002259592,0.0003656408,0.004700606,0.003242017,0.0007517008,0.005110042,0.00009951586],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964429,0.001686094,0.0001502235,0.00007288761,0.0000218041,0.000172391,0.0009970291,0.000009182746,0.0004474052],"genre_scores_gemma":[0.9962699,0.0005624602,0.0001804113,0.0001346335,0.00004989448,0.0001905794,0.002224969,0.000007572649,0.0003795481],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001753663,"threshold_uncertainty_score":0.007291019,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06474043651843095,"score_gpt":0.4448199058786346,"score_spread":0.3800794693602036,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}